相似文献
1
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
J Natl Compr Canc Netw. 2016 May;14(5):509-19. doi: 10.6004/jnccn.2016.0060.
2
NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.
J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61. doi: 10.6004/jnccn.2015.0181.
3
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.
J Natl Compr Canc Netw. 2023 Mar;21(3):236-246. doi: 10.6004/jnccn.2023.0014.
4
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.
J Natl Compr Canc Netw. 2014 Sep;12(9):1211-9; quiz 1219. doi: 10.6004/jnccn.2014.0120.
5
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063.
6
NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024.
J Natl Compr Canc Netw. 2024 Apr;22(3):140-150. doi: 10.6004/jnccn.2024.0019.
7
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008.
8
Prostate cancer early detection. Clinical practice guidelines in oncology.
J Natl Compr Canc Netw. 2004 May;2(3):190-207. doi: 10.6004/jnccn.2004.0018.
9
Prostate cancer early detection clinical practice guidelines in oncology.
J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S42-55.
10
Point/Counterpoint: early detection of prostate cancer: do the benefits outweigh the consequences?
J Natl Compr Canc Netw. 2014 May;12(5 Suppl):768-71. doi: 10.6004/jnccn.2014.0186.
引用本文的文献
1
Deep-learning triage of 3D pathology datasets for comprehensive and efficient pathologist assessments.
bioRxiv. 2025 Jul 22:2025.07.20.665804. doi: 10.1101/2025.07.20.665804.
2
Low Testosterone Level and Mortality Risk in Patients With Prostate Cancer: A Post-Randomization Analysis.
Cancer Med. 2025 Aug;14(15):e71124. doi: 10.1002/cam4.71124.
3
Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.
Discov Oncol. 2025 May 30;16(1):954. doi: 10.1007/s12672-025-02763-1.
4
Multiparametric MRI to Predict Gleason Score Upgrading and Downgrading at Radical Prostatectomy Compared to Presurgical Biopsy.
Korean J Radiol. 2025 May;26(5):422-434. doi: 10.3348/kjr.2024.1008. Epub 2025 Mar 21.
5
Sebaceous Carcinoma of the Breast in a Japanese Male with a Pathogenic Variant: Report of an Exceedingly Rare Case and Review of the Literature.
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.24-00543. Epub 2025 Jan 31.
6
Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis.
Cancers (Basel). 2024 Nov 28;16(23):3995. doi: 10.3390/cancers16233995.
7
Age limit for familial prostate cancer screening.
Caspian J Intern Med. 2024 Oct 27;16(1):187-191. doi: 10.22088/cjim.16.1.187. eCollection 2025 Winter.
8
Prostate cancer theragnostics biomarkers: An update.
Investig Clin Urol. 2024 Nov;65(6):527-539. doi: 10.4111/icu.20240229.
9
Trends in pre-biopsy MRI usage for prostate cancer detection, 2007-2022.
Prostate Cancer Prostatic Dis. 2025 Jun;28(2):519-522. doi: 10.1038/s41391-024-00896-y. Epub 2024 Sep 21.
10
Association of Prostate-Specific Antigen With Age, Digital Rectal Examination, and Lower Urinary Tract Symptoms in the Lebanese Population: A Cross-Sectional Study.
Cureus. 2024 Aug 16;16(8):e66991. doi: 10.7759/cureus.66991. eCollection 2024 Aug.
本文引用的文献
1
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
J Clin Oncol. 2015 Sep 1;33(25):2789-96. doi: 10.1200/JCO.2014.59.8912. Epub 2015 Jul 20.
2
Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
Urol Oncol. 2015 Oct;33(10):424.e17-23. doi: 10.1016/j.urolonc.2015.05.032. Epub 2015 Jul 7.
3
Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Eur Urol. 2016 Mar;69(3):419-25. doi: 10.1016/j.eururo.2015.05.024. Epub 2015 May 29.
4
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
J Natl Cancer Inst. 2015 Apr 11;107(7). doi: 10.1093/jnci/djv095. Print 2015 Jul.
5
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
BJU Int. 2016 Jan;117(1):72-9. doi: 10.1111/bju.13139. Epub 2015 May 24.
6
Age at cancer diagnosis for blacks compared with whites in the United States.
J Natl Cancer Inst. 2015 Jan 31;107(3). doi: 10.1093/jnci/dju489. Print 2015 Mar.
7
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
JAMA. 2015 Jan 27;313(4):390-7. doi: 10.1001/jama.2014.17942.
8
9
Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis.
Eur Urol. 2015 Sep;68(3):438-50. doi: 10.1016/j.eururo.2014.11.037. Epub 2014 Dec 3.
10
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27.
Zotero 插件